Sonnet BioTherapeutics Holdings, Inc. (SONN) Tops Q1 EPS by 33c

Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) reported Q1 EPS of ($0.80), $0.33 better than the analyst estimate of ($1.13). Revenue for the quarter came in at $40 thousand versus the consensus estimate of $100 thousand.

For earnings history and earnings-related data on Sonnet BioTherapeutics Holdings, Inc. (SONN) click here.

You May Also Be Interested In

• ​Trump said he was unaware of his earnings from crypto
• Berenberg Starts Brooks Macdonald Group PLC (BRK:LN) at Buy
• Pembina joins proposed 1M bbl/day Alberta-to-coast pipeline plan